Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Immuneering Corp (IMRX)

Immuneering Appoints Grant C. Bogle as Class III Director

Neutral Impact 2 of 5 leadership

Immuneering's Board appointed Grant C. Bogle, MBA, as a Class III director on November 9, 2026. He will receive the standard non-employee director compensation and has signed the company's standard director and officer indemnification agreement, but has not yet been named to a Board committee.

Key points

  • Appointed to the Board as a Class III Director on November 9, 2026
  • Compensated under the company's non-employee director arrangements
  • No committee assignment at this time
  • No arrangement or understanding under which Bogle was elected, per the filing

The filing

CompanyImmuneering Corp (IMRX)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:16 PM ET
Accession number0001790340-26-000099

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.